It’s Time To Focus On The Long Run With Acorda Therapeutics Inc. (ACOR) stock

Acorda Therapeutics Inc. (NASDAQ: ACOR) closed the day trading at $0.62 up 7.60% from the previous closing price of $0.57. In other words, the price has increased by $+0.0436 from its previous closing price. On the day, 127397 shares were traded. ACOR stock price reached its highest trading level at $0.6200 during the session, while it also had its lowest trading level at $0.6000.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.



For a better understanding of ACOR, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.30 and its Current Ratio is at 1.70. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 2.48.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, H.C. Wainwright on June 17, 2021, Upgraded its rating to Buy and sets its target price to $10 from $5 previously.

On August 14, 2019, H.C. Wainwright Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $31 to $6.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 17 when COHEN RON sold 2,289 shares for $1.70 per share. The transaction valued at 3,895 led to the insider holds 129,601 shares of the business.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 0.12 while its Price-to-Book (P/B) ratio in mrq is 0.20.

Stock Price History:

Over the past 52 weeks, ACOR has reached a high of $3.43, while it has fallen to a 52-week low of $0.26. The 50-Day Moving Average of the stock is 0.5166, while the 200-Day Moving Average is calculated to be 0.8652.

Shares Statistics:

Over the past 3-months, ACOR traded about 3.83M shares per day on average, while over the past 10 days, ACOR traded about 347.43k shares per day. A total of 24.29M shares are outstanding, with a floating share count of 24.17M. Insiders hold about 0.10% of the company’s shares, while institutions hold 25.80% stake in the company. Shares short for ACOR as of Oct 13, 2022 were 792.03k with a Short Ratio of 1.47M, compared to 221.81k on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 3.25% and a Short% of Float of 3.27%.

Earnings Estimates

Current recommendations for the stock of the company come from 0 analysts. On average, analysts expect EPS of $0 for the current quarter, with a high estimate of $0 and a low estimate of $0, while EPS last year was -$2.5. The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.

Analysts are recommending an EPS of between $0 and $0 for the fiscal current year, implying an average EPS of $0. EPS for the following year is $0, with 0 analysts recommending between $0 and $0.

Revenue Estimates

1 analysts predict $36.97M in revenue for the current quarter. It ranges from a high estimate of $31.01M to a low estimate of $31.01M. As of the current estimate, Acorda Therapeutics Inc.’s year-ago sales were $38.16M, an estimated decrease of -3.10% from the year-ago figure. For the next quarter, 1 analysts are estimating revenue of $26M, a decrease of -9.90% less than the figure of -$3.10% in the same quarter last year. There is a high estimate of $26M for the next quarter, whereas the lowest estimate is $26M.

A total of 1 analysts have provided revenue estimates for ACOR’s current fiscal year. The highest revenue estimate was $120.38M, while the lowest revenue estimate was $120.38M, resulting in an average revenue estimate of $129.07M. In the same quarter a year ago, actual revenue was $152.97M, down -15.60% from the average estimate. Based on 1 analysts’ estimates, the company’s revenue will be $120.51M in the next fiscal year. The high estimate is $120.51M and the low estimate is $120.51M. The average revenue growth estimate for next year is down -6.60% from the average revenue estimate for this year.